Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells-Reference-Cited by-同舟云学术

Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells

Published:2024-06-07 Issue:2 Volume:13 Page:45
ISSN:2073-4468
Container-title:Antibodies
language:en
Short-container-title:Antibodies

Author:

Zhou Guangyu¹²,Fu Shengyu¹,Zhang Yunsen³,Li Shuang⁴,Guo Ziang¹,Ouyang Defang³^ORCID,Ying Tianlei⁵^ORCID,Lu Yinying⁴,Zhao Qi¹²^ORCID

Affiliation:

1. Institute of Translational Medicine, Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa 999078, Macau SAR, China

2. MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa 999078, Macau SAR, China

3. Institute of Chinese Medical Sciences, University of Macau, Taipa 999078, Macau SAR, China

4. The Fifth Medical Center of the PLA General Hospital, Beijing 100036, China

5. MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

Abstract

Chimeric antigen receptor (CAR) T cell therapy shows promise in treating malignant tumors. However, the use of human epidermal growth factor receptor-2 (HER2) CAR-T cells carries the risk of severe toxicity, including cytokine release syndrome, due to their “on-target off-tumor” recognition of HER2. Enhancing the quality and functionality of HER2 CARs could greatly improve the therapeutic potential of CAR-T cells. In this study, we developed a novel anti-HER2 monoclonal antibody, Ab8, which targets domain III of HER2, distinct from the domain IV recognition of trastuzumab. Although two anti-HER2 mAbs induced similar levels of antibody-dependent cellular cytotoxicity, trastuzumab-based CAR-T cells exhibited potent antitumor activity against HER2-positive cancer cells. In conclusion, our findings provide scientific evidence that antibody recognition of the membrane-proximal domain promotes the anti-tumor response of HER2-specific CAR-T cells.

Funder

National Key R&D Program of China

Natural Science Foundation of Guangdong Province

Science and Technology Development Fund of Macau

University of Macau

Publisher

MDPI AG

Link

https://www.mdpi.com/2073-4468/13/2/45/pdf

Reference30 articles.

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Essadi, I., Benbrahim, Z., Kaakoua, M., Reverdy, T., Corbaux, P., and Freyer, G. (2023). HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments. Cancers, 15.

3. Duro-Sanchez, S., Alonso, M.R., and Arribas, J. (2023). Immunotherapies against HER2-Positive Breast Cancer. Cancers, 15.

4. Recombinant-fully-human-antibody decorated highly-stable far-red AIEdots for in vivo HER-2 receptor-targeted imaging;Wu;Chem. Commun.,2018

5. Targeting HER2-positive breast cancer: Advances and future directions;Swain;Nat. Rev. Drug Discov.,2023